Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2017 from OUS - Section for gastrointestinal oncology

17 publications found

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG (2017)
Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study
Radiother Oncol, 123 (3), 446-453
DOI 10.1016/j.radonc.2017.04.012, PubMed 28483302

Astrup GL, Hofsø K, Bjordal K, Guren MG, Vistad I, Cooper B, Miaskowski C, Rustøen T (2017)
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
Acta Oncol, 56 (3), 462-470
DOI 10.1080/0284186X.2016.1273546, PubMed 28077018

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Byskov CS, Nyvang L, Guren MG, Spindler KLG, Muren LP (2017)
The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer
Phys. Imag. Radiat. Oncol., 3, 43-48
DOI 10.1016/j.phro.2017.09.001

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H (2017)
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Eur J Surg Oncol, 43 (9), 1682-1689
DOI 10.1016/j.ejso.2017.04.010, PubMed 28522174

Grut H, Dueland S, Line PD, Revheim ME (2017)
The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases
Eur J Nucl Med Mol Imaging, 45 (2), 218-225
DOI 10.1007/s00259-017-3843-9, PubMed 29026950

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S (2017)
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases
Br J Surg, 105 (3), 295-301
DOI 10.1002/bjs.10651, PubMed 29168565

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Labori KJ, Guren MG, Brudvik KW, Røsok BI, Waage A, Nesbakken A, Larsen S, Dueland S, Edwin B, Bjørnbeth BA (2017)
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384

Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S (2017)
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial
BMC Surg, 17 (1), 94
DOI 10.1186/s12893-017-0291-1, PubMed 28841916

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Rusten E, Rekstad BL, Undseth C, Al-Haidari G, Hanekamp B, Hernes E, Hellebust TP, Malinen E, Guren MG (2017)
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205

Sodergren SC, Johnson CD, Gilbert A, Tomaszewski KA, Chu W, Chung HT, Dennis K, Desideri I, Glynne-Jones R, Grønlie Guren M, Kardamakis D, Nugent K, Schmidt H, Sebag-Montefiore D, Vassiliou V, EORTC Quality of Life Group (2017)
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Radiother Oncol, 126 (2), 222-228
DOI 10.1016/j.radonc.2017.11.018, PubMed 29217122

Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M (2017)
Quality of life as a prognostic factor for survival in hepatocellular carcinoma
Liver Int, 38 (5), 885-894
DOI 10.1111/liv.13593, PubMed 28941130

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH (2017)
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Target Oncol, 12 (1), 97-109
DOI 10.1007/s11523-016-0469-y, PubMed 27975152

 
Page visits: 648322